Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein

Premkumar Christadoss, Elzbieta Goluszko

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Lymphotoxin-α (TNF-β) and TNF receptor p55 gene knockout mice are resistant to the development of antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG), suggesting a possible role of TNF in mediating EAMG. Therefore, we tested the hypothesis that blocking the functional interaction of TNF with their receptors by soluble recombinant human TNFR:Fc would suppress the ongoing clinical EAMG. Recombinant human TNFR:Fc administered daily for 2 weeks to C57BL6 mice with ongoing clinical EAMG significantly improved clinical EAMG when compared with placebo-treated mice. A clinical trial of selected myasthenia gravis patients with recombinant human TNFR:Fc could be attempted.

Original languageEnglish (US)
Pages (from-to)186-190
Number of pages5
JournalJournal of Neuroimmunology
Volume122
Issue number1-2
DOIs
StatePublished - 2002

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Tumor Necrosis Factor Receptors
Proteins
Therapeutics
Lymphotoxin-alpha
Gene Knockout Techniques
Myasthenia Gravis
Knockout Mice
Placebos
human TNF protein
Clinical Trials
Antibodies

Keywords

  • Autoimmunity
  • Cytokine
  • Myasthenia gravis
  • Therapy
  • TNF receptor

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. / Christadoss, Premkumar; Goluszko, Elzbieta.

In: Journal of Neuroimmunology, Vol. 122, No. 1-2, 2002, p. 186-190.

Research output: Contribution to journalArticle

@article{77718abf7eec49b8ba20800cdcf8cc06,
title = "Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein",
abstract = "Lymphotoxin-α (TNF-β) and TNF receptor p55 gene knockout mice are resistant to the development of antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG), suggesting a possible role of TNF in mediating EAMG. Therefore, we tested the hypothesis that blocking the functional interaction of TNF with their receptors by soluble recombinant human TNFR:Fc would suppress the ongoing clinical EAMG. Recombinant human TNFR:Fc administered daily for 2 weeks to C57BL6 mice with ongoing clinical EAMG significantly improved clinical EAMG when compared with placebo-treated mice. A clinical trial of selected myasthenia gravis patients with recombinant human TNFR:Fc could be attempted.",
keywords = "Autoimmunity, Cytokine, Myasthenia gravis, Therapy, TNF receptor",
author = "Premkumar Christadoss and Elzbieta Goluszko",
year = "2002",
doi = "10.1016/S0165-5728(01)00473-8",
language = "English (US)",
volume = "122",
pages = "186--190",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein

AU - Christadoss, Premkumar

AU - Goluszko, Elzbieta

PY - 2002

Y1 - 2002

N2 - Lymphotoxin-α (TNF-β) and TNF receptor p55 gene knockout mice are resistant to the development of antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG), suggesting a possible role of TNF in mediating EAMG. Therefore, we tested the hypothesis that blocking the functional interaction of TNF with their receptors by soluble recombinant human TNFR:Fc would suppress the ongoing clinical EAMG. Recombinant human TNFR:Fc administered daily for 2 weeks to C57BL6 mice with ongoing clinical EAMG significantly improved clinical EAMG when compared with placebo-treated mice. A clinical trial of selected myasthenia gravis patients with recombinant human TNFR:Fc could be attempted.

AB - Lymphotoxin-α (TNF-β) and TNF receptor p55 gene knockout mice are resistant to the development of antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG), suggesting a possible role of TNF in mediating EAMG. Therefore, we tested the hypothesis that blocking the functional interaction of TNF with their receptors by soluble recombinant human TNFR:Fc would suppress the ongoing clinical EAMG. Recombinant human TNFR:Fc administered daily for 2 weeks to C57BL6 mice with ongoing clinical EAMG significantly improved clinical EAMG when compared with placebo-treated mice. A clinical trial of selected myasthenia gravis patients with recombinant human TNFR:Fc could be attempted.

KW - Autoimmunity

KW - Cytokine

KW - Myasthenia gravis

KW - Therapy

KW - TNF receptor

UR - http://www.scopus.com/inward/record.url?scp=0036145585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036145585&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(01)00473-8

DO - 10.1016/S0165-5728(01)00473-8

M3 - Article

VL - 122

SP - 186

EP - 190

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -